by editor | Sep 2, 2013 | Asides, Blog
Pacific Biosciences of California – NasdaqGS: PACB The Company is set with the cash it needs for now. They are making progress. The recent conference call had CEO Michael Hunkapiller noting, “We booked new orders for 7 PacBio RS II systems and installed 3 systems,...
by editor | Sep 2, 2013 | Asides, Blog
Novavax Inc. NasdaqGS: NVAX There have been a ton of insider buys for NVAX over the past six months, with only a single sell. The positive news from the company is very reassuring. So much so for current investors, the stock has been setting new 52 week highs lately....
by editor | Sep 2, 2013 | Asides, Blog
IGI Laboratories Inc. NYSE MKT: IG Their press release that gives bullet points about the most recent 10-K is a great source of information here. These tell the short story: Second Quarter and Year to Date 2013 Highlights Total revenues of $3.8 million in the second...
by editor | Sep 2, 2013 | Asides, Blog
Idenix Pharmaceuticals Inc. NasdaqGS: IDIX This is one high beta stock. The swings are notorious here, and you would likely not buy at current levels if you were ONLY looking at the chart: Quoting Ron Renaud, the President and CEO for Idenix, from the August 7th...
by editor | Sep 2, 2013 | Asides, Blog
Concord Medical Services NYSE: CCM Let’s look at the latest quarterly results. Then let’s look at the CEO and COO acquiring shares from other shareholders. Second Quarter 2013 Highlights Total net revenue, which consists of net revenues generated from the network...